Drug Profile
Fremanezumab - Teva Pharmaceutical Industries
Alternative Names: AJOVY; Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; fremanezumab-vfrm; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Rinat Neuroscience
- Developer Otsuka Pharmaceutical; Rinat Neuroscience; Teva Pharmaceutical Industries
- Class Analgesics; Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II Fibromyalgia; Headache; Interstitial cystitis
- Discontinued Cluster headache